KALA BIO, Inc. financial data

Symbol
KALA on Nasdaq
Location
1167 Massachusetts Avenue, Arlington, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 230 % -48%
Debt-to-equity 794 % +61.1%
Return On Equity -686 % -73.3%
Return On Assets -76.8 % -14.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.02M shares +52.4%
Common Stock, Shares, Outstanding 6.68M shares +45.2%
Entity Public Float 23.9M USD -29.9%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 6.51M shares +115%
Weighted Average Number of Shares Outstanding, Diluted 6.51M shares +115%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.23M USD +17.2%
General and Administrative Expense 17.8M USD -7.65%
Operating Income (Loss) -41.1M USD -3.07%
Nonoperating Income (Expense) 3.92M USD +226%
Net Income (Loss) Attributable to Parent -37.2M USD +3.85%
Earnings Per Share, Basic -5 USD/shares +55.8%
Earnings Per Share, Diluted -5 USD/shares +55.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.9M USD -41.1%
Assets, Current 33.7M USD -42.8%
Property, Plant and Equipment, Net 657K USD +6.48%
Operating Lease, Right-of-Use Asset 1.51M USD -19.1%
Assets 36.1M USD -41.5%
Accounts Payable, Current 658K USD -1.05%
Employee-related Liabilities, Current 1.51M USD +109%
Accrued Liabilities, Current 4.5M USD -28.2%
Liabilities, Current 16M USD -16.5%
Operating Lease, Liability, Noncurrent 1.23M USD -24.6%
Liabilities 39.3M USD -18%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -688M USD -5.72%
Stockholders' Equity Attributable to Parent -3.21M USD -123%
Liabilities and Equity 36.1M USD -41.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.6M USD
Net Cash Provided by (Used in) Financing Activities -135K USD -102%
Net Cash Provided by (Used in) Investing Activities -13K USD +88%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 6.68M shares +45.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.96M USD -271%
Interest Paid, Excluding Capitalized Interest, Operating Activities 909K USD -20.5%
Deferred Tax Assets, Valuation Allowance 140M USD +8.37%
Deferred Tax Assets, Gross 140M USD +8.22%
Operating Lease, Liability 1.63M USD -17.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37.2M USD +3.87%
Property, Plant and Equipment, Gross 2.06M USD +10.7%
Operating Lease, Liability, Current 406K USD +14%
Lessee, Operating Lease, Liability, to be Paid, Year Two 644K USD +3.54%
Lessee, Operating Lease, Liability, to be Paid, Year One 622K USD +3.49%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 379K USD -38.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 440K USD -31.7%
Deferred Tax Assets, Operating Loss Carryforwards 121M USD +11.2%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 440K USD -31.7%
Operating Lease, Payments 591K USD +24.4%
Additional Paid in Capital 685M USD +3.06%
Depreciation, Depletion and Amortization 68K USD +3.03%
Share-based Payment Arrangement, Expense 8.68M USD -3.94%
Interest Expense 5.8M USD -13.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%